{"filing":{"accession_number":"0001437749-26-030900","cik":"0001385818","ticker":"AYTU","company_name":"AYTU BIOPHARMA, INC","form":"8-K","filing_date":"2026-09-22","report_date":"2026-09-22","primary_document":"aytu20260502_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774926030900/aytu20260502_8k.htm"},"events":[{"id":34301,"run_id":31568,"accession_number":"0001437749-26-030900","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"The filing discloses Aytu BioPharma's fiscal 2026 fourth quarter and full-year operational and financial results via a press release (Exhibit 99.1). The disclosure includes detailed revenue figures by product portfolio, gross profit, operating expenses, net loss, Adjusted EBITDA, and cash position—all standard components of an earnings release. The company explicitly scheduled a conference call for September 22, 2026, to discuss these results, which is typical for earnings announcements.","company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","filing_date":"2026-09-22","form":"8-K","submitted_at":null,"items":[{"id":37985,"accession_number":"0001437749-26-030900","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses Aytu BioPharma's fiscal 2026 fourth quarter and full-year operational and financial results via a press release (Exhibit 99.1). The disclosure includes detailed revenue figures by product portfolio, gross profit, operating expenses, net loss, Adjusted EBITDA, and cash position—all standard components of an earnings release. The company explicitly scheduled a conference call for September 22, 2026, to discuss these results, which is typical for earnings announcements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:07:49.358564+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37985,"accession_number":"0001437749-26-030900","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses Aytu BioPharma's fiscal 2026 fourth quarter and full-year operational and financial results via a press release (Exhibit 99.1). The disclosure includes detailed revenue figures by product portfolio, gross profit, operating expenses, net loss, Adjusted EBITDA, and cash position—all standard components of an earnings release. The company explicitly scheduled a conference call for September 22, 2026, to discuss these results, which is typical for earnings announcements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:07:49.358564+00:00","company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","filing_date":"2026-09-22"}]}